Page last updated: 2024-09-03

imatinib mesylate and Eosinophilia, Tropical

imatinib mesylate has been researched along with Eosinophilia, Tropical in 87 studies

Research

Studies (87)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	39 (44.83)	29.6817
2010's	35 (40.23)	24.3611
2020's	13 (14.94)	2.80

Authors

Authors	Studies
Brunner, AM; Dal Cin, P; De Angelo, DJ; Dias-Santagata, D; Iafrate, AJ; Le, LP; Lennerz, JK; Luskin, MR; Marble, HD; Mueller, SB; Nardi, V; Stone, RM; Weinstock, MJ	1
Fujii, T; Kitahara, S; Kobayashi, S; Matsui, T; Matsunaga, T; Ohno, N; Sahara, N; Sakamoto, N	1
Abermil, N; Badaoui, B; Bontoux, C; Crickx, E; Dubois, S; Favre, L; Guermouche, H; Michel, M; Pécriaux, A; Poullot, E; Quang, VT; Roy, L; Sloma, I; Tarfi, S; Wang, L; Xuan, JV	1
Gotlib, J	1
Al-Qattan, Y; Ali, S; AlShemmari, S; Awny, W; Hamadah, A; Pinto, K	1
Coltro, G; Santi, R	1
Adam, M; Bröckelmann, PJ; Wienemann, H	1
Cross, NCP; Fabarius, A; Haferlach, T; Hochhaus, A; Hofmann, WK; Jawhar, M; Metzgeroth, G; Naumann, N; Reiter, A; Schwaab, J	1
Dal Cin, P; Ebert, BL; Grinshpun, DE; Hobbs, GS; Iafrate, AJ; Jan, M; Nardi, V; Sykes, DB; Villalba, JA	1
Chen, Y; Cheng, Z; Luo, Y; Peng, H; Wang, Y; Xu, Y; Zhang, G; Zhang, Y	1
Goodarzi, H; Novoa, R; Teng, JMC; Wang, J; Wu, TT	1
Barkoh, BA; Bueso-Ramos, CE; Chen, W; Fang, H; Futreal, A; Gupta, SK; Jain, N; Khoury, JD; Loghavi, S; Luthra, R; Mao, X; Medeiros, LJ; Patel, KP; Routbort, M; Tang, G; Wang, SA; Yang, RK; Zhang, J	1
Cai, P; Chen, S; Lu, Q; Ma, L; Ruan, C; Wang, M; Wang, Z; Xu, X; Zeng, Z; Zhang, L	1
Baer, MR; Hoppman, NL; Kotiah, SD; Sawhney, S; Singh, ZN; Zou, YS	1
Kalhagen, L; Leighton, L; McGrath, K; Stein, B	1
Baurmann, H; Casper, J; Cross, NCP; Dang, TA; Dietze, L; Döhner, K; Fabarius, A; Haferlach, C; Haferlach, T; Hänel, A; Hochhaus, A; Hofmann, WK; Jawhar, M; Lathan, B; Link, H; Lotfi, S; Maywald, O; Metzgeroth, G; Mielke, S; Müller, L; Naumann, N; Panse, J; Platzbecker, U; Prümmer, O; Reiter, A; Schwaab, J; Thomssen, H; Töpelt, K; Vieler, T	1
Hawes, V; Lobo, RH; Sasapu, A; Socola, F	1
Li, Y; Tu, S; Wang, Y; Wu, Q; Xia, L; Yang, J; Zhang, M; Zhao, M	1
Aouinti, I; Badri, T; Charfi, O; Elaidli, S; Kastalli, S; Lakhoua, G; Zaïem, A; Zgolli, F	1
Baker, A; Scordino, T; Srinivasan, A	1
Fukazawa, M; Hatanaka, Y; Iseki, T; Ishizuka, Y; Mimura, N; Mitsukawa, S; Muto, T; Nakaseko, C; Ohwada, C; Oshima-Hasegawa, N; Ozawa, S; Sakaida, E; Takeda, Y; Takeuchi, M; Tsukamoto, S; Yamazaki, M	1
Cross, NC; Fabarius, A; Gosenca, D; Haferlach, C; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Schwaab, J	1
Fancher, KM; Green, MR; Newton, MD	1
Garcia-Manero, G; Khoury, JD; Loghavi, S; Shah, S	1
Aguiar, RC; Apperley, JF; Burbury, K; Cheah, CY; Cross, NC; Dunbar, CE; Forrest, D; Gardembas, M; Genet, P; Gimelfarb, A; Huguet, F; Ito, S; Odenike, O; Patton, N; Pitini, V; Ross, DM; Rousselot, P; Seymour, JF; Smith, G	1
Cross, NC; Erben, P; Fabarius, A; Gosenca, D; Haferlach, C; Haferlach, T; Hofmann, WK; Kellert, B; Kneba, M; Metzgeroth, G; Reiter, A; Scheid, C; Schwaab, J; Seifarth, W; Töpelt, K	1
Kristensen, TK; Møller, MB; Rathe, M; Schomerus, E; Wehner, PS	1
Ali, SM; Campregher, PV; Chalmers, ZR; Chmielecki, J; Elvin, JA; Erlich, R; Frampton, GM; Hermann, R; Miles, CR; Miller, VA; Ohgami, RS; Palma, NA; Ross, JS; Stephens, PJ; Vergilio, JA; Yelensky, R	1
Bogdanovic, A; Elezovic, I; Gotic, M; Jankovic, G; Lekovic, D; Perunicic-Jovanovic, M	1
Jeon, J; Koh, YI; Ryang, DW; Won, EJ	1
Cross, NC; Dang, TA; Dietz, CT; Fabarius, A; Gärtner, M; Göhring, G; Haferlach, C; Hofmann, WK; Jawhar, M; Lotfi, S; Metzgeroth, G; Naumann, N; Reiter, A; Schlegelberger, B; Schnittger, S; Schwaab, J	1
Feng, S; Han, M; He, Y; Liu, Q; Shi, Y; Yang, D; Zhang, R	1
Barraco, D; Elala, Y; Lasho, T; Pardanani, A; Patnaik, M; Tefferi, A	1
Chelysheva, EY; Galstyan, GM; Khuazheva, NK; Kovrigina, AM; Nemchenko, IS; Savchenko, VG; Turkina, AG	1
Bedwell, C; Greystoke, B; McGregor, AK; Oakes, R; Wood, K	1
Abdelmalek, C; Andrei, M; Bandarchuk, A; Gotlieb, V; Kundra, A; Wang, JC	1
Cross, NC; Erben, P; Gosenca, D; Haferlach, C; Hänel, A; Hochhaus, A; Metzgeroth, G; Reiter, A; Walz, C	1
de Revel, T; Fagot, T; Konopacki, J; Malfuson, JV; Mangouka, L; Souleau, B	1
Atallah, E; Bredeson, C; Bryke, C; Divgi, A; Kroft, SH; Nand, R	1
Di, YW; Liu, YH; Zhuang, HG	1
Jotterand, M; Muehlematter, D; Rausch, T; Spertini, O; Stalder, M; Védy, D	1
Liu, L; Qin, TJ; Xiao, ZJ; Zhang, Y; Zhou, CL	1
Gotlib, J; Pardanani, A; Tefferi, A	1
Carlsen, NL; Kristensen, TK; Møller, MB; Rathe, M	1
Gau, JP; Hsiao, LT; Liu, CY; Pai, JT; Teng, HW; Tzeng, CH; Wang, JR; Yen, CC	1
Cheung, WY; Ksienski, D	1
Dumon-Gubeno, MC; Figueredo, M; Medioni, LD; Mouroux, J; Naman, H; Nicolle, I; Tarhini, A; Vandenbos, F	1
Abraham, S; Fluchel, M; Hancock, J; Jacobsen, J; Salama, M	1
D'Souza, A; Hanson, CA; Ketterling, RP; Knudson, RA; Pardanani, A; Tefferi, A	1
Alrwas, A; Juneja, HS; Marcos, LA; Mehta, SS; Nguyen, ND; Quesada, JR; Shattuck, BL	1
Bagot, M; Battistella, M; Flageul, B; Galicier, L; Hickman, G; Isvy-Joubert, A; Petit, A	1
Ali, S; Cross, NC; Dickinson, H; Hidalgo-Curtis, C; Jack, A; Score, J; Waghorn, K; Winkelmann, N	1
Anastasi, J; Hossain, NM; Jain, N; McConville, JF; Odenike, O; Steinmetz, JL	1
Apperley, JF; Bain, BJ; Baxter, EJ; Chase, A; Chessells, JM; Colombat, M; Cross, NC; Dearden, CE; Dimitrijevic, S; Gardembas, M; Goldman, JM; Mahon, FX; Marin, D; Melo, JV; Nikolova, Z; Olavarria, E; Russell-Jones, R; Schultheis, B; Silberman, S	1
Schwartz, RS	1
Alo, G; Arrigo, C; Barresi, G; Pitini, V; Righi, M; Teti, D	1
Brockman, SR; Cools, J; Cross, NC; Dewald, GW; Flynn, HC; Gilliland, DG; Ketterling, RP; Li, CY; Pardanani, A; Paternoster, SF; Reeder, TL; Shearer, BM; Tefferi, A	1
Aguiar, RC; Aster, JC; Lee, C; Lopes, LF; Shipp, MA; Velloso, ER; Wilkinson, K	1
Bloomfield, K; Braunschweig, I; Chadburn, A; Darji, J; Gotlib, V; Patel, A	1
Coutré, S; Gotlib, J	1
Bain, B	1
Elliott, MA; Li, CY; Pardanani, A; Tefferi, A	1
Pardanani, A; Tefferi, A	2
Tefferi, A	2
Brockman, SR; Dewald, GW; Flynn, HC; Ho, CL; Ketterling, RP; Lasho, TL; Li, CY; Pardanani, A; Paternoster, SF; Tefferi, A	1
Baxter, EJ; Burgstaller, S; Chase, AJ; Cross, NC; Grand, FH; Kühr, T; Thaler, J; Webersinke, G	1
Borbényi, Z	1
Clément, JF; Contentin, N; Courville, P; Jardin, F; Laquerriere, A; Lehembre, S; Lenain, P; Lenormand, B; Pouplin, S; Tilly, H	1
Butterfield, JH; Camoriano, JK; Dewald, GW; Elliott, MA; Ketterling, RP; Li, CY; Pardanani, A; Patnaik, MM; Tefferi, A; Wolanskyj, AP	1
Boveri, E; Chichino, G; Cilloni, D; Daniela, C; Emanuela, B; Enrico, G; Giovanni, M; Gottardi, E; Guido, C; Martinelli, G; Merante, S; Serena, M; Simona, S; Soverini, S	1
Charlanne, H; Prin, L	1
Robyn, J	1
Bober, G; Grosicki, S; Helbig, G; Hochhaus, A; Holowiecki, J; Krawczyk, M; Reiter, A; Stella-Holowiecka, B; Wojnar, J	1
Pardanani, A; Patnaik, MM; Tefferi, A	1
Gotoh, M; Kawasugi, K; Noguchi, M; Shirafuji, N; Shirasaki, R; Tashiro, H	1
Naithani, R; Panigrahi, I	1
Augustson, B; Cannell, P; Joske, D; Willson, A	1
Campos, L; Cornillon, J; Delabesse, E; Flandrin, P; Mauvieux, L; Morel, S; Nadal, N; Olaru, D	1
Apperley, JF; Burgstaller, S; Chase, A; Cross, NC; Curtis, C; Dang, R; David, M; Gardembas, M; Goldman, JM; Grand, F; Hughes, G; Huguet, F; Lavender, L; Mahon, FX; Massimini, G; McArthur, GA; Melo, J; Nikolova, Z; Rousselot, P; Russell-Jones, RJ; Seymour, JF; Smith, G; Stark, A; Waghorn, K	1
Butterfield, J; Kantarjian, H; Ketterling, R; Pardanani, A; Tefferi, A; Vaklavas, C; Verstovsek, S	1
Aulitzky, WE; Beneke, H; Cross, NC; Del Valle, F; Diecker, F; Döhner, H; Erben, P; Haferlach, C; Haferlach, T; Hehlmann, R; Hochhaus, A; Hodges, E; Metzgeroth, G; Mix, J; Müller, L; Müller, MC; Müller-Hermelink, K; Popp, H; Reiter, A; Schmitz, N; Schnittger, S; Schuld, P; Schulte, C; Score, J; Siebert, R; Walz, C; Whittaker, SJ; Wittkowsky, G	1
Clark, D; Lyall, H; O'Connor, S	1
Kalac, M; Kantarjian, H; Quintás-Cardama, A; Verstovsek, S; Vrhovac, R	1
England, RW; Scranton, SE; Wild, CA	1
Hamano, Y; Isobe, Y; Nitta, H; Oshimi, K; Sasaki, M; Sato, E; Sugimoto, K; Tomomatsu, J	1

Reviews

16 review(s) available for imatinib mesylate and Eosinophilia, Tropical

Article	Year
Available and emerging therapies for bona fide advanced systemic mastocytosis and primary eosinophilic neoplasms. Hematology. American Society of Hematology. Education Program, 2022, 12-09, Volume: 2022, Issue:1 Topics: Child; Eosinophilia; Humans; Imatinib Mesylate; Mastocytosis; Mastocytosis, Systemic; Myeloproliferative Disorders; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit	2022
Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature. Journal of global oncology, 2018, Volume: 4 Topics: Antineoplastic Agents; Biomarkers; Bone Marrow; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha; Tumor Lysis Syndrome	2018
Off-Target Effects of BCR-ABL and JAK2 Inhibitors. American journal of clinical oncology, 2016, Volume: 39, Issue:1 Topics: Aniline Compounds; Antineoplastic Agents; Carbazoles; Dasatinib; Drug-Related Side Effects and Adverse Reactions; Eosinophilia; Furans; Fusion Proteins, bcr-abl; Gastrointestinal Stromal Tumors; Graft vs Host Disease; Harringtonines; Homoharringtonine; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Imidazoles; Janus Kinase 2; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mastocytosis; Myeloproliferative Disorders; Nitriles; Polycythemia Vera; Primary Myelofibrosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Pyrazoles; Pyridazines; Pyrimidines; Quinolines; Scleroderma, Systemic; Smallpox; Thrombocythemia, Essential; Tuberculosis, Multidrug-Resistant	2016
[Treatment of adult acute lymphoblastie leukemia with eosinophilia and abnormality of PDGFRA by autologous hematopoietic stem cell transplantation and imatinib: one case report and literatures review]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2015, Volume: 36, Issue:10 Topics: Adult; Eosinophilia; Hematopoietic Stem Cell Transplantation; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptor, Platelet-Derived Growth Factor alpha	2015
PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review. The American journal of case reports, 2017, Feb-17, Volume: 18 Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Dose-Response Relationship, Drug; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Leukocyte Count; Leukocytosis; Male; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2017
Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update. Mayo Clinic proceedings, 2010, Volume: 85, Issue:2 Topics: Alemtuzumab; Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Causality; Decision Trees; Diagnosis, Differential; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myelomonocytic, Chronic; Mastocytosis; mRNA Cleavage and Polyadenylation Factors; Mutation; Myelodysplastic Syndromes; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptors, Platelet-Derived Growth Factor	2010
Eosinophilic variant of chronic myeloid leukemia with vascular complications. Leukemia & lymphoma, 2003, Volume: 44, Issue:9 Topics: Adult; Anticoagulants; Antineoplastic Agents; Benzamides; Bone Marrow; Diagnostic Errors; Eosinophilia; Fingers; Gangrene; Humans; Imatinib Mesylate; Leg; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Pain; Piperazines; Pyrimidines; Radiography; Vasculitis; Vitamins	2003
Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate. Seminars in cancer biology, 2004, Volume: 14, Issue:1 Topics: Animals; Benzamides; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Substrate Specificity	2004
Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders. Leukemia research, 2004, Volume: 28 Suppl 1 Topics: Benzamides; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2004
Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis. International journal of hematology, 2004, Volume: 79, Issue:5 Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; DNA Mutational Analysis; Eosinophilia; Humans; Imatinib Mesylate; Mastocytosis, Systemic; Piperazines; Pyrimidines; Receptors, Platelet-Derived Growth Factor	2004
Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clinic proceedings, 2005, Volume: 80, Issue:1 Topics: Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines	2005
[Disorders with eosinophilia, treatment of hypereosinophilic syndrome]. Orvosi hetilap, 2005, May-01, Volume: 146, Issue:18 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Decision Trees; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate; Interferon-alpha; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2005
[Treatment of hypereosinophilia]. Presse medicale (Paris, France : 1983), 2006, Volume: 35, Issue:1 Pt 2 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzamides; Chronic Disease; Cyclosporins; Drug Resistance; Eosinophilia; Glucocorticoids; Humans; Hydroxyurea; Imatinib Mesylate; Immunologic Factors; Immunosuppressive Agents; Interferon-alpha; Myeloproliferative Disorders; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Recurrence; Time Factors	2006
Eosinophilia: secondary, clonal and idiopathic. British journal of haematology, 2006, Volume: 133, Issue:5 Topics: Benzamides; Bone Marrow; Chromosome Aberrations; Cytokines; Eosinophilia; Gene Rearrangement; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Parasitic Diseases; Piperazines; Protein Kinase Inhibitors; Pulmonary Eosinophilia; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2006
Imatinib mesylate: A designer drug. The Journal of the Association of Physicians of India, 2006, Volume: 54 Topics: Benzamides; Eosinophilia; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Philadelphia Chromosome; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyrimidines	2006
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia. Cancer, 2007, Sep-01, Volume: 110, Issue:5 Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Benzamides; Clone Cells; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Treatment Outcome	2007

Trials

5 trial(s) available for imatinib mesylate and Eosinophilia, Tropical

Article	Year
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase. Annals of hematology, 2017, Volume: 96, Issue:9 Topics: Abnormal Karyotype; Adult; Aged; Aged, 80 and over; Blast Crisis; Disease-Free Survival; Eosinophilia; Female; Follow-Up Studies; Gene Rearrangement; Hematologic Neoplasms; Humans; Imatinib Mesylate; Male; Middle Aged; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; Sex Factors; Survival Rate	2017
[The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2009, Volume: 30, Issue:6 Topics: Adult; Aged; Benzamides; Eosinophilia; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome; Young Adult	2009
A novel pathogenetic mutation in clonal eosinophilia. Current hematology reports, 2004, Volume: 3, Issue:3 Topics: Benzamides; Cell Division; Cell Line, Transformed; Chromosome Deletion; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 4; Clone Cells; DNA Mutational Analysis; Eosinophilia; Humans; Imatinib Mesylate; Inhibitory Concentration 50; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Translocation, Genetic	2004
Molecular analysis of chronic eosinophilic leukemia with t(4;10) showing good response to imatinib mesylate. International journal of hematology, 2006, Volume: 83, Issue:5 Topics: Adult; Asian People; Benzamides; Chromosomes, Human, Pair 10; Chromosomes, Human, Pair 4; Chronic Disease; Enzyme Activation; Eosinophilia; Follow-Up Studies; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Leukemic; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Time Factors; Translocation, Genetic	2006
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia, 2007, Volume: 21, Issue:6 Topics: Acute Disease; Adult; Aged; Benzamides; Disease-Free Survival; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Nucleophosmin; Oncogene Proteins, Fusion; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein-Tyrosine Kinases; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction	2007

Other Studies

66 other study(ies) available for imatinib mesylate and Eosinophilia, Tropical

Article	Year
t(4;12)(q12;p13) ETV6-rearranged AML without eosinophilia does not involve PDGFRA: relevance for imatinib insensitivity. Blood advances, 2022, 01-08, Volume: 6, Issue:3 Topics: Eosinophilia; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myeloid, Acute; Receptor Protein-Tyrosine Kinases; Retrospective Studies	2022
[Successful treatment with imatinib for a patient with myeloid neoplasms with eosinophilia and abnormalities of PDGFRB due to t (5;14)(q33;q22)]. [Rinsho ketsueki] The Japanese journal of clinical hematology, 2021, Volume: 62, Issue:11 Topics: Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Neoplasms; Receptor, Platelet-Derived Growth Factor beta	2021
[Myeloid neoplasms associated with rearrangement of PDGFRB: A rare and tricky disease]. Annales de pathologie, 2022, Volume: 42, Issue:6 Topics: Aged; Eosinophilia; Hematologic Neoplasms; Humans; Imatinib Mesylate; Immunoglobulins, Intravenous; In Situ Hybridization, Fluorescence; Male; Myeloproliferative Disorders; Receptor, Platelet-Derived Growth Factor beta	2022
FIP1L1-PDGFRA fusion gene in T-lymphoblastic lymphoma: A case report. Cancer reports (Hoboken, N.J.), 2023, Volume: 6, Issue:1 Topics: Child; Eosinophilia; Humans; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Receptor, Platelet-Derived Growth Factor alpha	2023
A challenging diagnosis of myeloid/lymphoid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement. Blood, 2023, 05-18, Volume: 141, Issue:20 Topics: Eosinophilia; Humans; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2023
[Complete remission of Loeffler's endocarditis with Imatinib in a myeloid and lymphoid neoplasm associated with eosinophilia]. Deutsche medizinische Wochenschrift (1946), 2020, Volume: 145, Issue:1 Topics: Antineoplastic Agents; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma; Male; Middle Aged	2020
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation. Blood advances, 2020, Feb-11, Volume: 4, Issue:3 Topics: Eosinophilia; Hematologic Neoplasms; Humans; Imatinib Mesylate; Remission Induction; Retrospective Studies; Survival Rate	2020
A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia. Blood advances, 2020, 02-11, Volume: 4, Issue:3 Topics: DNA Helicases; Eosinophilia; Humans; Imatinib Mesylate; Male; Neoplasms; Poly-ADP-Ribose Binding Proteins; Receptor, Platelet-Derived Growth Factor beta; RNA Helicases; RNA Recognition Motif Proteins; Young Adult	2020
A novel NAP1L4/NUTM1 fusion arising from translocation t(11;15)(p15;q12) in a myeloid neoplasm with eosinophilia and rearrangement of PDGFRA highlights an unusual clinical feature and therapeutic reaction. Annals of hematology, 2020, Volume: 99, Issue:7 Topics: Adult; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 15; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Male; Mutation; Myeloproliferative Disorders; Neoplasm Proteins; Nuclear Proteins; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Translocation, Genetic	2020
Imatinib as a potentially effective therapeutic alternative in corticosteroid-resistant eosinophilic fasciitis. Pediatric dermatology, 2020, Volume: 37, Issue:6 Topics: Adrenal Cortex Hormones; Child; Eosinophilia; Fasciitis; Humans; Imatinib Mesylate; Male	2020
A Cryptic BCR-PDGFRB Fusion Resulting in a Chronic Myeloid Neoplasm With Monocytosis and Eosinophilia: A Novel Finding With Treatment Implications. Journal of the National Comprehensive Cancer Network : JNCCN, 2020, Volume: 18, Issue:10 Topics: Eosinophilia; Humans; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2020
Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia. Cancer research and treatment, 2021, Volume: 53, Issue:3 Topics: Adult; Biopsy; Bone Marrow; Casein Kinase II; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Treatment Outcome	2021
Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. Cancer genetics, 2017, Volume: 212-213 Topics: Antigens, Nuclear; Cell Cycle Proteins; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 5; Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Nuclear Matrix-Associated Proteins; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic; Treatment Outcome	2017
Imatinib mesylate- and dasatinib-induced eosinophilia in a patient with chronic myelocytic leukemia. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2017, Volume: 119, Issue:1 Topics: Aged; Antineoplastic Agents; Dasatinib; Eosinophilia; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Protein Kinase Inhibitors	2017
Identification of a novel PDGFRA point mutation at p.P6L as a potential molecular target of imatinib in an eosinophilia patient showing genetic heterogeneity. Cancer biology & therapy, 2019, Volume: 20, Issue:4 Topics: Adult; Antineoplastic Agents; Eosinophilia; Genetic Heterogeneity; Humans; Imatinib Mesylate; Male; Oncogene Proteins, Fusion; Point Mutation; Prognosis; Receptor, Platelet-Derived Growth Factor alpha	2019
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Imatinib. Current drug safety, 2019, Volume: 14, Issue:2 Topics: Antineoplastic Agents; Eosinophilia; Exanthema; Female; Humans; Imatinib Mesylate; Middle Aged	2019
Myeloid Neoplasm With Eosinophilia and FIP1L1-PDGFRA Rearrangement Treated With Imatinib Mesylate: A Pediatric Case With Long-term Follow-up. Journal of pediatric hematology/oncology, 2019, Volume: 41, Issue:4 Topics: Adolescent; Antineoplastic Agents; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2019
Myeloid/Lymphoid Neoplasm with PDGFRB Rearrangement with t (5;10) (q33;q22) Harboring a Novel Breakpoint of the CCDC6-PDGFRB Fusion Gene. Internal medicine (Tokyo, Japan), 2019, Dec-01, Volume: 58, Issue:23 Topics: Antineoplastic Agents; Cytoskeletal Proteins; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2019
Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase. Leukemia, 2013, Volume: 27, Issue:11 Topics: Antineoplastic Agents; Benzamides; Blast Crisis; Eosinophilia; Follow-Up Studies; Gene Rearrangement; Humans; Imatinib Mesylate; Leukemia, Myeloid; Lymphoma, T-Cell; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Sarcoma, Myeloid; Survival Rate	2013
Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia. Journal of hematology & oncology, 2014, Mar-27, Volume: 7 Topics: Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib. Blood, 2014, Jun-05, Volume: 123, Issue:23 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Child; Child, Preschool; Eosinophilia; Female; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid; Male; Middle Aged; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic; Young Adult	2014
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Genes, chromosomes & cancer, 2014, Volume: 53, Issue:5 Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 5; Chronic Disease; DNA-Binding Proteins; Eosinophilia; Gene Fusion; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Leukemia; Male; Microfilament Proteins; Molecular Sequence Data; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic	2014
Relapse of myeloid neoplasm with eosinophilia and PDGFRA rearrangement after imatinib discontinuation in a pediatric patient. Pediatric blood & cancer, 2014, Volume: 61, Issue:12 Topics: Antineoplastic Agents; Benzamides; Child, Preschool; Eosinophilia; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Myeloproliferative Disorders; Neoplasm Recurrence, Local; Piperazines; Prognosis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Withholding Treatment	2014
Comprehensive genomic profiling identifies a novel TNKS2-PDGFRA fusion that defines a myeloid neoplasm with eosinophilia that responded dramatically to imatinib therapy. Blood cancer journal, 2015, Feb-06, Volume: 5 Topics: Benzamides; Eosinophilia; Female; Genome, Human; High-Throughput Nucleotide Sequencing; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Tankyrases	2015
Diagnostic challenges during pretreatment long-term follow-up in a patient with FIP1L1-PDGFRA-positive eosinophilia. Internal medicine (Tokyo, Japan), 2015, Volume: 54, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Follow-Up Studies; Humans; Imatinib Mesylate; Leukemia, Myeloid; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2015
Strongyloidiasis in a diabetic patient accompanied by gastrointestinal stromal tumor: cause of eosinophilia unresponsive to steroid therapy. The Korean journal of parasitology, 2015, Volume: 53, Issue:2 Topics: Aged; Albendazole; Animals; Diabetes Mellitus, Type 2; Eosinophilia; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Steroids; Strongyloides stercoralis; Strongyloidiasis	2015
Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Genes, chromosomes & cancer, 2015, Volume: 54, Issue:12 Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 3; Chromosomes, Human, Pair 5; Cytogenetic Analysis; Eosinophilia; Gene Fusion; Golgi Matrix Proteins; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Male; Membrane Proteins; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic	2015
Next generation sequencing of myeloid neoplasms with eosinophilia harboring the FIP1L1-PDGFRA mutation. American journal of hematology, 2016, Volume: 91, Issue:3 Topics: Adult; Aged; Bone Marrow; Disease-Free Survival; Eosinophilia; Eosinophils; Female; Humans; Imatinib Mesylate; Leukocyte Count; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2016
[FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy]. Terapevticheskii arkhiv, 2015, Volume: 87, Issue:12 Topics: Adult; Dasatinib; Eosinophilia; Female; Humans; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Multiple Organ Failure; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha	2015
Pathological fracture due to lytic lesion caused by a myeloid neoplasm with FIP1L1-PDGFRA. British journal of haematology, 2016, Volume: 174, Issue:5 Topics: Adult; Eosinophilia; Femur Neck; Fractures, Bone; Humans; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasms; Oncogene Proteins, Fusion; Receptor, Platelet-Derived Growth Factor alpha	2016
Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Genes, chromosomes & cancer, 2009, Volume: 48, Issue:2 Topics: Antineoplastic Agents; Benzamides; Chromosome Painting; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 5; Eosinophilia; Gene Fusion; Humans; Imatinib Mesylate; Male; Middle Aged; Mutant Chimeric Proteins; Myelodysplastic-Myeloproliferative Diseases; Myosins; Piperazines; Polymerase Chain Reaction; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2009
[Hematological disorders and hypereosinophilias]. La Revue de medecine interne, 2009, Volume: 30, Issue:4 Topics: Antineoplastic Agents; Benzamides; Eosinophilia; Gene Rearrangement; Glucocorticoids; Hematologic Diseases; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukemia; Piperazines; Pyrimidines; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta	2009
Myeloproliferative disorder with eosinophilia and ETV6-ABL gene rearrangement: efficacy of second-generation tyrosine kinase inhibitors. Leukemia research, 2009, Volume: 33, Issue:8 Topics: Benzamides; Eosinophilia; Female; Gene Rearrangement; Humans; Imatinib Mesylate; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Remission Induction	2009
[Eosinophils and related diseases]. Zhonghua bing li xue za zhi = Chinese journal of pathology, 2009, Volume: 38, Issue:7 Topics: Antineoplastic Agents; Autoimmune Diseases; Benzamides; Cell Differentiation; Cell Movement; Cell Survival; Eosinophilia; Eosinophils; Helminthiasis; Humans; Hypereosinophilic Syndrome; Hypersensitivity; Imatinib Mesylate; Piperazines; Pyrimidines	2009
Acute myeloid leukemia with myeloid sarcoma and eosinophilia: prolonged remission and molecular response to imatinib. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-20, Volume: 28, Issue:3 Topics: Antineoplastic Agents; Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Sarcoma, Myeloid	2010
Myeloid neoplasm with prominent eosinophilia and PDGFRA rearrangement treated with imatinib mesylate. Pediatric blood & cancer, 2010, Volume: 55, Issue:4 Topics: Benzamides; Child, Preschool; Eosinophilia; Female; Gene Rearrangement; Humans; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2010
A case of myeloid neoplasm associated with eosinophilia and KIAA1509-PDGFRβ responsive to combination treatment with imatinib mesylate and prednisolone. Journal of clinical pharmacy and therapeutics, 2010, Volume: 35, Issue:6 Topics: Adult; Antineoplastic Agents, Hormonal; Benzamides; Drug Therapy, Combination; Eosinophilia; Eosinophils; Female; Gene Fusion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Leukocyte Count; Myeloproliferative Disorders; Piperazines; Prednisolone; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta	2010
Metastatic uterine leiomyosarcoma and eosinophilia. Obstetrics and gynecology, 2011, Volume: 117, Issue:2 Pt 2 Topics: Antineoplastic Agents; Benzamides; Dyspnea; Eosinophilia; Fatal Outcome; Female; Humans; Hydroxyurea; Imatinib Mesylate; Leiomyosarcoma; Liver Neoplasms; Lung Neoplasms; Middle Aged; Piperazines; Prednisone; Pyrimidines; Splenic Neoplasms; Uterine Neoplasms	2011
[Clonal eosinophilia revealed by recurrent Staphylococcus aureus infection]. Revue de pneumologie clinique, 2011, Volume: 67, Issue:3 Topics: Anti-Bacterial Agents; Benzamides; Biomarkers; Clone Cells; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Risk Factors; Smoking; Staphylococcal Infections; Staphylococcus aureus; Treatment Outcome	2011
Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib. Pediatric blood & cancer, 2012, Volume: 59, Issue:5 Topics: Antineoplastic Agents; Benzamides; Child, Preschool; Eosinophilia; Humans; Imatinib Mesylate; Infant, Newborn; Infant, Newborn, Diseases; Male; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta	2012
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcome. Leukemia, 2012, Volume: 26, Issue:11 Topics: Adult; Aged; Benzamides; Eosinophilia; Female; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Survival Analysis; Treatment Outcome	2012
Case of polycythemia vera concurrent with FIP1L1-PDGFRA-positive myeloproliferative neoplasm with eosinophilia. Cancer genetics, 2012, Volume: 205, Issue:10 Topics: Antineoplastic Agents; Benzamides; Biopsy; Eosinophilia; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Models, Genetic; mRNA Cleavage and Polyadenylation Factors; Mutation; Myeloproliferative Disorders; Piperazines; Polycythemia Vera; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction	2012
[Myeloproliferative hypereosinophilic syndrome revealed by bipolar mucosal ulcerations]. Annales de dermatologie et de venereologie, 2012, Volume: 139, Issue:10 Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Diagnosis, Differential; Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mucous Membrane; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pulmonary Eosinophilia; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Skin Ulcer	2012
Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. Leukemia & lymphoma, 2013, Volume: 54, Issue:7 Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Chromosome Breakpoints; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 6; Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic; Treatment Outcome	2013
A 32-year-old man with persistent cough, shortness of breath, eosinophilic pneumonia, and peripheral blood eosinophilia. Myeloid neoplasm associated with eosinophilia and platelet-derived growth factor receptor-alpha rearrangement. Chest, 2012, Volume: 142, Issue:6 Topics: Adult; Antineoplastic Agents; Benzamides; Bone Marrow Neoplasms; Cough; Dyspnea; Eosinophilia; Gene Rearrangement; Humans; Imatinib Mesylate; Male; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pulmonary Eosinophilia; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Steroids; Treatment Outcome	2012
Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. The New England journal of medicine, 2002, Aug-15, Volume: 347, Issue:7 Topics: Adult; Aged; Benzamides; Child; Chromosomes, Human, Pair 5; DNA-Binding Proteins; Eosinophilia; ETS Translocation Variant 6 Protein; Gene Rearrangement; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukocytosis; Male; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ets; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Repressor Proteins	2002
The hypereosinophilic syndrome and the biology of cancer. The New England journal of medicine, 2003, Mar-27, Volume: 348, Issue:13 Topics: Benzamides; Chromosome Deletion; Enzyme Inhibitors; Eosinophilia; Eosinophils; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; T-Lymphocytes; Translocation, Genetic	2003
Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report. Haematologica, 2003, Volume: 88, Issue:5 Topics: Aged; Antineoplastic Agents; Benzamides; Enzyme Inhibitors; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelomonocytic, Chronic; Male; Myelodysplastic Syndromes; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Translocation, Genetic	2003
CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood, 2003, Nov-01, Volume: 102, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Benzamides; Eosinophilia; Gene Rearrangement; Hematopoietic Stem Cells; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Mastocytosis, Systemic; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Predictive Value of Tests; Prospective Studies; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Treatment Outcome	2003
Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood, 2003, Dec-01, Volume: 102, Issue:12 Topics: Benzamides; Chromosomes, Human, Pair 1; Chromosomes, Human, Pair 5; Clone Cells; Cloning, Molecular; Eosinophilia; Female; Humans; Imatinib Mesylate; Infant; Microtubule-Associated Proteins; Myeloproliferative Disorders; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Remission Induction; Translocation, Genetic	2003
The idiopathic hypereosinophilic syndrome and eosinophilic leukemias. Haematologica, 2004, Volume: 89, Issue:2 Topics: Benzamides; Clone Cells; Cytokines; Eosinophilia; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Lymphoma; Models, Biological; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; T-Lymphocyte Subsets	2004
Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis. Leukemia, 2004, Volume: 18, Issue:5 Topics: Adult; Benzamides; Bone Marrow Cells; Eosinophilia; Humans; Imatinib Mesylate; Immunophenotyping; Male; Mast Cells; Mastocytosis, Systemic; Piperazines; Pyrimidines	2004
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood, 2004, Nov-15, Volume: 104, Issue:10 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Bone Marrow; Cohort Studies; DNA-Binding Proteins; Eosinophilia; Female; Gene Deletion; Humans; Imatinib Mesylate; Incidence; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prevalence; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Severity of Illness Index; Transcription Factors	2004
p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Cancer research, 2004, Oct-15, Volume: 64, Issue:20 Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzamides; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 5; Eosinophilia; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Male; Molecular Sequence Data; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Phosphoproteins; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Reverse Transcriptase Polymerase Chain Reaction; Translocation, Genetic; Tumor Suppressor p53-Binding Protein 1	2004
Concomitant eosinophilia, fasciitis, and mycosis fungoides-like reaction with antinuclear autoantibodies in chronic myeloid leukaemia: role of a T-cell clone induced by imatinib. The Lancet. Oncology, 2005, Volume: 6, Issue:9 Topics: Aged; Antibodies, Antinuclear; Antineoplastic Agents; Benzamides; Eosinophilia; Fasciitis; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mycosis Fungoides; Piperazines; Pseudolymphoma; Pyrimidines	2005
FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leukemia research, 2006, Volume: 30, Issue:8 Topics: Adult; Aged; Benzamides; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Eosinophilia; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Oncogene Proteins, Fusion; Piperazines; Prevalence; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Recurrence; Remission Induction; Treatment Outcome	2006
First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4 Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Agents; Benzamides; Eosinophilia; Humans; Imatinib Mesylate; Male; Mastocytosis, Systemic; Monomeric GTP-Binding Proteins; Piperazines; Polymorphism, Restriction Fragment Length; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction	2006
Imatinib-responsive hypereosinophilic syndrome. Leukemia research, 2006, Volume: 30, Issue:8 Topics: Benzamides; Dose-Response Relationship, Drug; Eosinophilia; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Remission Induction; Treatment Outcome	2006
The results of imatinib therapy for patients with primary eosinophilic disorders. European journal of haematology, 2006, Volume: 76, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Drug Evaluation; Eosinophilia; Female; Follow-Up Studies; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Neoplasm Proteins; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Treatment Outcome	2006
Imatinib-induced cytogenetic remission in chronic eosinophilic leukaemia. Internal medicine journal, 2006, Volume: 36, Issue:8 Topics: Benzamides; Chronic Disease; Cytogenetic Analysis; Eosinophilia; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction	2006
Successful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophilia. Cancer genetics and cytogenetics, 2006, Volume: 169, Issue:2 Topics: Benzamides; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 5; Chronic Disease; Eosinophilia; Humans; Imatinib Mesylate; Male; Middle Aged; Myeloproliferative Disorders; Piperazines; Pyrimidines; Translocation, Genetic	2006
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. Blood, 2007, Jan-01, Volume: 109, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Child; Child, Preschool; Drug Evaluation; Eosinophilia; Female; Follow-Up Studies; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Infant; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Translocation, Genetic; Treatment Outcome	2007
'Idiopathic' eosinophilia with an Occult T-cell clone: prevalence and clinical course. Leukemia research, 2007, Volume: 31, Issue:5 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clone Cells; Cyclophosphamide; Eosinophilia; Female; Humans; Imatinib Mesylate; Leukemia, Lymphoid; Lymphoma, T-Cell, Peripheral; Male; Methotrexate; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Oncogene Proteins, Fusion; Piperazines; Prevalence; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; T-Lymphocytes	2007
Charcot-Leyden crystals in the trephine biopsy of a patient with a FIP1L1-PDGFRA - positive myeloproliferative disorder. British journal of haematology, 2007, Volume: 138, Issue:4 Topics: Antineoplastic Agents; Benzamides; Biopsy; Bone Marrow; Bone Marrow Examination; Crystallization; Eosinophilia; Glycoproteins; Humans; Imatinib Mesylate; Lysophospholipase; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Myeloproliferative Disorders; Oncogene Proteins, Fusion; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha	2007
Episodic angioedema with eosinophilia: successful treatment with imatinib. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, 2008, Volume: 100, Issue:2 Topics: Angioedema; Antineoplastic Agents; Benzamides; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Diagnosis, Differential; Eosinophilia; Female; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Pyrimidines; Recurrence	2008
Multiple brain infarctions induced by imatinib mesylate in a patient with clonal eosinophilia. International journal of hematology, 2008, Volume: 87, Issue:4 Topics: Benzamides; Brain Infarction; Eosinophilia; Humans; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Middle Aged; Piperazines; Pyrimidines	2008